Retinoid X receptor α enhances human cholangiocarcinoma growth through simultaneous activation of Wnt/β-catenin and nuclear factor-κB pathways

Cancer Science

Volumn 106, Issue 11, 2015, Pages 1515-1523

  Huang, Gui Li ^a   Zhang, Wei ^b   Ren, Hong Yue ^b   Shen, Xue Ying ^a   Chen, Qing Xi ^a   Shen, Dong Yan ^b  

^a XIAMEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; NF B; Proliferation; Retinoid X receptor ; catenin

Indexed keywords

BETA CATENIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN E; CYCLINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P21; RETINOID X RECEPTOR ALPHA; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL EVALUATION; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; UPREGULATION; BILE DUCT TUMOR; CELL SURVIVAL; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VERY ELDERLY; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; BILE DUCT NEOPLASMS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHOLANGIOCARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; RETINOID X RECEPTOR ALPHA; SIGNAL TRANSDUCTION; TRANSFECTION; WNT PROTEINS;

EID: 84983123733     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12802     Document Type: Article

References (35)

1. Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis Model Mech 2013; 6: 281-92.
2. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-67.
3. Ramia JM. Hilar cholangiocarcinoma. World J Gastrointest Oncol 2013; 5: 113-4.
4. Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: an update. World J Gastrointest Oncol 2013; 5: 171-6.
5. Gronemeyer H, Gustafsson J-Å, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discovery 2004; 3: 950-64.
6. Maire A, Alvarez S, Shankaranarayanan P, Lera AR, Bourguet W, Gronemeyer H. Retinoid receptors and therapeutic applications of RAR/RXR modulators. Curr Top Med Chem 2012; 12: 505-27.
7. Zhong C, Yang S, Huang J, Cohen MB, Roy-Burman P. Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther 2003; 2: 179-84.
8. Crowe DL, Chandraratna RA. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 2004; 6: R546-55.
9. Takiyama Y, Miyokawa N, Sugawara A et al. Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 5851-61.
10. Miyazaki S, Taniguchi H, Moritoh Y et al. Nuclear hormone retinoid X receptor (RXR) negatively regulates the glucose-stimulated insulin secretion of pancreatic ss-cells. Diabetes 2010; 59: 2854-61.
11. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
12. Zhu J, Nasr R, Pérès L et al. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007; 12: 23-35.
13. Dawson MI, Zhang X-K. Discovery and design of retinoic acid receptor and retinoid X receptor class- and subtype-selective synthetic analogs of all-trans-retinoic acid and 9-cis-retinoic acid. Curr Med Chem 2002; 9: 623-37.
14. Kempf W, Kettelhack N, Duvic M, Burg G. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003; 17: 1405-19.
15. Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther 2003; 16: 322-30.
16. Chen Q, Li W, Wan Y et al. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways. Hepatology 2012; 55: 1820-9.
17. Huang GL, Luo Q, Rui G et al. Oncogenic activity of retinoic acid receptor gamma is exhibited through activation of the Akt/NF-kappaB and Wnt/beta-catenin pathways in cholangiocarcinoma. Mol Cell Biol 2013; 33: 3416-25.
18. Shen DY, Fang ZX, You P et al. Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int 2010; 30: 119-25.
19. Chikazawa N, Tanaka H, Tasaka T et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 2010; 30: 2041-8.
20. Flahaut M, Meier R, Coulon A et al. The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/beta-catenin pathway. Oncogene 2009; 28: 2245-56.
21. Shtutman M, Zhurinsky J, Simcha I et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999; 96: 5522-7.
22. Zhang H, Zhang X, Wu X et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/beta-catenin pathway. Cancer Lett 2012; 323: 106-13.
23. Perez E, Bourguet W, Gronemeyer H, de Lera AR. Modulation of RXR function through ligand design. Biochim Biophys Acta 2012; 1821: 57-69.
24. Fukunaka K, Saito T, Wataba K, Ashihara K, Ito E, Kudo R. Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle. Mol Hum Reprod 2001; 7: 437-46.
25. Zhang F, Meng F, Li H, Dong Y, Yang W, Han A. Suppression of retinoid X receptor alpha and aberrant beta-catenin expression significantly associates with progression of colorectal carcinoma. Eur J Cancer 2011; 47: 2060-7.
26. Lawrence JA, Merino MJ, Simpson JF, Manrow RE, Page DL, Steeg PS. A high-risk lesion for invasive breast cancer, ductal carcinoma in situ, exhibits frequent overexpression of retinoid X receptor. Cancer Epidemiol Biomarkers Prev 1998; 7: 29-35.
27. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
28. Hahnvajanawong C, Ketnimit S, Pattanapanyasat K et al. Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin. Biol Pharm Bull 2012; 35: 1914-25.
29. Banito A, Gil J. Induced pluripotent stem cells and senescence: learning the biology to improve the technology. EMBO Rep 2010; 11: 353-9.
30. Batheja N, Suriawinata A, Saxena R, Ionescu G, Schwartz M, Thung SN. Expression of p53 and PCNA in cholangiocarcinoma and primary sclerosing cholangitis. Mod Pathol 2000; 13: 1265-8.
31. Tokumoto N, Ikeda S, Ishizaki Y et al. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 2005; 27: 973-80.
32. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192-205.
33. Shen DY, Zhang W, Zeng X, Liu CQ. Inhibition of Wnt/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma. Cancer Sci 2013; 104: 1303-8.
34. Xiao JH, Ghosn C, Hinchman C et al. Adenomatous polyposis coli (APC)-independent regulation of beta-catenin degradation via a retinoid X receptor-mediated pathway. J Biol Chem 2003; 278: 29954-62.
35. Gu X, Ke S, Liu D et al. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006; 281: 17882-9.